VivoSeq
Other

Lymphoproliferative Disorders

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Lymphoproliferative Disorders is an early-stage landscape with 0 programs across 2 companies. The most active players are HemaQuest Pharmaceuticals Inc., Atara Biotherapeutics.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

HemaQuest Pharmaceuticals Inc.

0 programs

PreclinicalA

Atara Biotherapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed11 · 73%
Terminated2 · 13%
Withdrawn1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Recruiting·—·Phase 1·NCT06672705·26 enrolled
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
Completed·SSundsvall Hospital·Phase 3·NCT00145652·66 enrolled
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
Completed·—·Phase 2·NCT04463615·1 enrolled
Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
Completed·GGruppo Italiano Studio Linfomi·N/A·NCT01224769·109 enrolled
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00001533·25 enrolled
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
Completed·NNorthwestern University·Phase 2·NCT00005606
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Completed·—·Phase 1·NCT00006340
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Completed·National Cancer Institute (NCI)·Phase 2·NCT00023764·103 enrolled
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00052572·35 enrolled
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
Completed·DDEKK-TEC, Inc.·Phase 1·NCT00002153·25 enrolled
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Completed·AAtara Biotherapeutics·Phase 2·NCT01498484·87 enrolled
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Completed·NNational Research Center for Hematology, Russia·Phase 1/2·NCT06705530·58 enrolled
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03601819·4 enrolled
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Terminated·HHemaQuest Pharmaceuticals Inc.·Phase 2·NCT00992732·1 enrolled
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT00968461

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)